Conrad Chan

989 total citations
32 papers, 772 citations indexed

About

Conrad Chan is a scholar working on Radiology, Nuclear Medicine and Imaging, Oncology and Pulmonary and Respiratory Medicine. According to data from OpenAlex, Conrad Chan has authored 32 papers receiving a total of 772 indexed citations (citations by other indexed papers that have themselves been cited), including 30 papers in Radiology, Nuclear Medicine and Imaging, 21 papers in Oncology and 4 papers in Pulmonary and Respiratory Medicine. Recurrent topics in Conrad Chan's work include Radiopharmaceutical Chemistry and Applications (26 papers), HER2/EGFR in Cancer Research (17 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). Conrad Chan is often cited by papers focused on Radiopharmaceutical Chemistry and Applications (26 papers), HER2/EGFR in Cancer Research (17 papers) and Monoclonal and Polyclonal Antibodies Research (17 papers). Conrad Chan collaborates with scholars based in Canada, United Kingdom and China. Conrad Chan's co-authors include Raymond M. Reilly, Zhongli Cai, Katherine A. Vallis, Deborah A. Scollard, Jean‐Philippe Pignol, Karen Lam, Paul Chen, Niladri Chattopadhyay, Judy Wang and Mitchell A. Winnik and has published in prestigious journals such as Biomacromolecules, International Journal of Pharmaceutics and Pharmaceutical Research.

In The Last Decade

Conrad Chan

31 papers receiving 765 citations

Peers — A (Enhanced Table)

Peers by citation overlap · career bar shows stage (early→late) cites · hero ref

Name	h						Papers	Cites
Conrad Chan Canada	16	504	261	213	158	82	32	772
Huiyun Zhao China	19	458 0.9×	263 1.0×	254 1.2×	124 0.8×	151 1.8×	38	894
R Boden United Kingdom	17	529 1.0×	200 0.8×	353 1.7×	89 0.6×	70 0.9×	28	801
Mihaela Ghita United Kingdom	16	293 0.6×	99 0.4×	215 1.0×	319 2.0×	146 1.8×	33	693
Erasmus Poku United States	14	419 0.8×	302 1.2×	156 0.7×	97 0.6×	107 1.3×	33	660
Christel Vangestel Belgium	18	364 0.7×	307 1.2×	401 1.9×	120 0.8×	120 1.5×	49	1.0k
Muhan Liu China	17	234 0.5×	78 0.3×	207 1.0×	105 0.7×	358 4.4×	33	725
Blesida Punzalan United States	11	202 0.4×	116 0.4×	142 0.7×	83 0.5×	67 0.8×	19	419
Gail Rowlinson‐Busza United Kingdom	14	258 0.5×	137 0.5×	307 1.4×	114 0.7×	134 1.6×	26	713
Thirupandiyur S. Udayakumar United States	13	103 0.2×	137 0.5×	267 1.3×	89 0.6×	142 1.7×	19	607
Guoliang Shao China	16	245 0.5×	96 0.4×	246 1.2×	86 0.5×	123 1.5×	53	711

Countries citing papers authored by Conrad Chan

Since Specialization

Citations

This map shows the geographic impact of Conrad Chan's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Conrad Chan with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Conrad Chan more than expected).

Fields of papers citing papers by Conrad Chan

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Conrad Chan. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Conrad Chan. The network helps show where Conrad Chan may publish in the future.

Co-authorship network of co-authors of Conrad Chan

This figure shows the co-authorship network connecting the top 25 collaborators of Conrad Chan. A scholar is included among the top collaborators of Conrad Chan based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Conrad Chan. Conrad Chan is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

Cai, Zhongli, et al.. (2024). Preclinical Comparison of [ ¹¹¹ In]In- and [ ²²⁵ Ac]Ac-DOTA-Trastuzumab IgG, F(ab′) ₂ and Fab for Theranostic SPECT/CT Imaging and α-Particle Radioimmunotherapy of HER2-Positive Human Breast Cancer. Molecular Pharmaceutics. 22(1). 474–487. 1 indexed citations

Nelson, Bryce J. B., John S. Wilson, Conrad Chan, et al.. (2024). SPECT/CT imaging of EGFR-positive head and neck squamous cell carcinoma patient-derived xenografts with 203Pb-PSC-panitumumab in NRG mice. EJNMMI Radiopharmacy and Chemistry. 9(1). 79–79.

Cai, Zhongli, et al.. (2023). [225Ac]Ac- and [111In]In-DOTA-trastuzumab theranostic pair: cellular dosimetry and cytotoxicity in vitro and tumour and normal tissue uptake in vivo in NRG mice with HER2-positive human breast cancer xenografts. EJNMMI Radiopharmacy and Chemistry. 8(1). 24–24. 8 indexed citations

Chan, Conrad, et al.. (2022). Formulation of a kit under Good Manufacturing Practices (GMP) for preparing [111In]In-BnDTPA-trastuzumab-NLS injection: a theranostic agent for imaging and Meitner-Auger Electron (MAE) radioimmunotherapy of HER2-positive breast cancer. EJNMMI Radiopharmacy and Chemistry. 7(1). 33–33. 3 indexed citations

Chan, Conrad, et al.. (2020). The pharmaceutical stability of trastuzumab after short-term storage at room temperature assessed by analytical techniques and tumour imaging by microSPECT/CT. International Journal of Pharmaceutics. 588. 119786–119786. 6 indexed citations

Boyle, Amanda J., et al.. (2020). Radioimmunotherapy of human pancreatic cancer xenografts in NOD-scid mice with [64Cu]Cu-NOTA-panitumumab F(ab′)2 alone or combined with radiosensitizing gemcitabine and the PARP inhibitor, rucaparib. Nuclear Medicine and Biology. 84-85. 46–54. 5 indexed citations

Chan, Conrad, Humphrey Fonge, Karen S.L. Lam, & Raymond M. Reilly. (2019). Effectiveness and normal tissue toxicity of Auger electron (AE) radioimmunotherapy (RIT) with [111In]In-Bn-DTPA-nimotuzumab in mice with triple-negative or trastuzumab-resistant human breast cancer xenografts that overexpress EGFR. Nuclear Medicine and Biology. 80-81. 37–44. 8 indexed citations

Lam, Karen, Conrad Chan, Susan J. Done, Mark N. Levine, & Raymond M. Reilly. (2014). Preclinical pharmacokinetics, biodistribution, radiation dosimetry and acute toxicity studies required for regulatory approval of a Clinical Trial Application for a Phase I/II clinical trial of 111In-BzDTPA-pertuzumab. Nuclear Medicine and Biology. 42(2). 78–84. 15 indexed citations

Lu, Yijie, Conrad Chan, Zhongli Cai, et al.. (2014). Synthesis of Polyglutamide-Based Metal-Chelating Polymers and Their Site-Specific Conjugation to Trastuzumab for Auger Electron Radioimmunotherapy. Biomacromolecules. 15(6). 2027–2037. 34 indexed citations

10.

Chan, Conrad, Zhongli Cai, & Raymond M. Reilly. (2013). Trastuzumab Labeled to High Specific Activity with 111In by Conjugation to G4 PAMAM Dendrimers Derivatized with Multiple DTPA Chelators Exhibits Increased Cytotoxic Potency on HER2-Positive Breast Cancer Cells. Pharmaceutical Research. 30(8). 1999–2009. 23 indexed citations

11.

Cai, Zhongli, et al.. (2011). Optimized digital counting colonies of clonogenic assays using ImageJ software and customized macros: Comparison with manual counting. International Journal of Radiation Biology. 87(11). 1135–1146. 91 indexed citations

12.

Chan, Conrad, et al.. (2011). A comparison of 111In- or 64Cu-DOTA-trastuzumab Fab fragments for imaging subcutaneous HER2-positive tumor xenografts in athymic mice using microSPECT/CT or microPET/CT. EJNMMI Research. 1(1). 15–15. 33 indexed citations

13.

McLarty, Kristin, Matthew Moran, Deborah A. Scollard, et al.. (2011). Comparisons of [18F]-1-deoxy-1-fluoro-scyllo-inositol with [18F]-FDG for PET imaging of inflammation, breast and brain cancer xenografts in athymic mice. Nuclear Medicine and Biology. 38(7). 953–959. 15 indexed citations

14.

Cai, Zhongli, Jean‐Philippe Pignol, Conrad Chan, & Raymond M. Reilly. (2010). Cellular Dosimetry of ¹¹¹In Using Monte Carlo N-Particle Computer Code: Comparison with Analytic Methods and Correlation with In Vitro Cytotoxicity. Journal of Nuclear Medicine. 51(3). 462–470. 54 indexed citations

15.

Scollard, Deborah A., Conrad Chan, Claire Holloway, & Raymond M. Reilly. (2010). A kit to prepare 111In-DTPA-trastuzumab (Herceptin) Fab fragments injection under GMP conditions for imaging or radioimmunoguided surgery of HER2-positive breast cancer. Nuclear Medicine and Biology. 38(1). 129–136. 18 indexed citations

16.

Chan, Conrad, et al.. (2007). 111In-Labeled Trastuzumab (Herceptin) Modified with Nuclear Localization Sequences (NLS): An Auger Electron-Emitting Radiotherapeutic Agent for HER2/neu-Amplified Breast Cancer. Journal of Nuclear Medicine. 48(8). 1357–1368. 148 indexed citations

17.

Chen, Paul, et al.. (2005). Site-specific conjugation of HIV-1 tat peptides to IgG: a potential route to construct radioimmunoconjugates for targeting intracellular and nuclear epitopes in cancer. European Journal of Nuclear Medicine and Molecular Imaging. 33(3). 301–310. 34 indexed citations

18.

Wang, Judy, Raymond M. Reilly, Paul Chen, et al.. (2002). Fusion of the C _H 1 Domain of IgG ₁ to Epidermal Growth Factor (EGF) Prolongs its Retention in the Blood but Does Not Increase Tumor Uptake. Cancer Biotherapy and Radiopharmaceuticals. 17(6). 665–671. 3 indexed citations

19.

Cheung, Yun‐Chung, et al.. (1997). The electron-dose distribution surrounding an 192Ir wire brachytherapy source investigated using EGS4 simulations and GafChromicTM film. Applied Radiation and Isotopes. 48(7). 985–990. 10 indexed citations

20.

Cheung, Yun‐Chung, et al.. (1997). The dose distribution close to an wire source: EGS4 Monte Carlo calculations. Physics in Medicine and Biology. 42(2). 401–406. 2 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact